TREM2-Targeting Therapies

TREM2-Targeting Therapies

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TREM2-Targeting Therapies</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">SHR-1707</td>
<td>Hengrui</td>
</tr>
<tr>
<td class="label">JBH-436</td>
<td>Janssen</td>
</tr>
</table>

Introduction

[TREM2](/proteins/trem2-protein) (Triggering Receptor Expressed on Myeloid Cells 2) has emerged as one of the most promising therapeutic targets in Alzheimer disease and other neurodegenerative conditions. This page provides comprehensive information about [TREM2](/genes/trem2) biology, therapeutic approaches, clinical development, and future directions.

Overview

TREM2 is a receptor expressed primarily on [microglia](/cell-types/microglia-neuroinflammation) in the central nervous system and has emerged as a critical therapeutic target for Alzheimer disease and other neurodegenerative conditions. TREM2 variants, particularly the R47H mutation, significantly increase Alzheimer disease risk, making it a high-priority target for drug development[@trem2013].

TREM2-Targeting Therapies

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TREM2-Targeting Therapies</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">SHR-1707</td>
<td>Hengrui</td>
</tr>
<tr>
<td class="label">JBH-436</td>
<td>Janssen</td>
</tr>
</table>

Introduction

[TREM2](/proteins/trem2-protein) (Triggering Receptor Expressed on Myeloid Cells 2) has emerged as one of the most promising therapeutic targets in Alzheimer disease and other neurodegenerative conditions. This page provides comprehensive information about [TREM2](/genes/trem2) biology, therapeutic approaches, clinical development, and future directions.

Overview

TREM2 is a receptor expressed primarily on [microglia](/cell-types/microglia-neuroinflammation) in the central nervous system and has emerged as a critical therapeutic target for Alzheimer disease and other neurodegenerative conditions. TREM2 variants, particularly the R47H mutation, significantly increase Alzheimer disease risk, making it a high-priority target for drug development[@trem2013].

TREM2 plays a central role in microglial function, including phagocytosis of amyloid plaques, neuroinflammation modulation, and metabolic adaptation. Therapeutic approaches aim to either activate TREM2 signaling or increase TREM2 expression to enhance microglial protective functions[@trem2017].

TREM2 Biology

Structure and Expression

• Receptor type: Single-pass transmembrane receptor of the immunoglobulin superfamily
• Primary expression: [Microglia](/cell-types/microglia) in the CNS, peripheral myeloid cells
• Ligands: Lipids, [amyloid-beta](/proteins/amyloid-beta), [apolipoprotein E](/proteins/apoe) (ApoE), TREM2 ligands
• Signaling: Associates with DAP12 (TYROBP) for intracellular signal transduction

Key Functions in Neurodegeneration

Phagocytosis: TREM2 is essential for microglial phagocytosis of:

• Amyloid-beta plaques
• Apoptotic [neurons](/entities/neurons)
• Cellular debris
• Pathological protein aggregates

• Cholesterol metabolism
• Lipid handling
• Energy production for inflammatory responses

• Promotes anti-inflammatory (M2-like) microglial phenotype
• Suppresses excessive pro-inflammatory responses
• Maintains tissue homeostasis

Genetic Association

The TREM2 R47H variant (rs75932628) increases AD risk approximately 3-fold, similar to [APOE](/proteins/apoe-protein) ε4[@trem2013a]. Other TREM2 variants associated with AD include:

• R62H
• D87N
• T96K
• Y38C

Therapeutic Approaches

1. TREM2 Agonists (Activating Antibodies)

TREM2 agonistic antibodies are designed to replicate the effect of natural TREM2 ligands and enhance microglial function. These antibodies bind to the extracellular domain of TREM2, triggering downstream signaling through DAP12.

AL002 (Alector/AbbVie)

• Humanized monoclonal antibody targeting TREM2
• Designed to activate TREM2 signaling and enhance microglial function
• Phase 2 clinical trials in early Alzheimer disease (INVOKE-2)
• Showed evidence of target engagement and reduced CSF sTREM2
• Phase 3 trials planned as of 2024

• Similar mechanism to AL002
• Different epitope binding properties
• Preclinical data showed enhanced plaque clearance

• TREM2-targeting antibody from Hengrui Therapeutics
• Entered Phase 1/2 clinical trials in China
• First China-developed TREM2 antibody for AD

2. TREM2 Expression Enhancers

These approaches aim to increase TREM2 protein levels in the brain through indirect mechanisms.

Anti-APOE Antibodies

• Reduce amyloid pathology and associated neuroinflammation
• May act partly through TREM2-dependent mechanisms
• Examples: simulengene body, celemab

• Reduce neuroinflammation that impairs TREM2 function
• Protect microglial TREM2 expression
• Several candidates in preclinical development

3. Small Molecule TREM2 Modulators

• Currently in preclinical development
• Challenge: Achieving sufficient brain penetration
• Focus on allosteric modulators of TREM2 signaling

4. Gene Therapy Approaches

• AAV-mediated TREM2 delivery to microglia
• CRISPR-based TREM2 editing
• Still in early preclinical stages

5. TREM2-Targeted Bispecific Antibodies

An emerging approach involves engineering antibodies that target TREM2 while also engaging other therapeutic targets:

• TREM2 x amyloid bispecifics
• TREM2 x [tau](/proteins/tau) bispecifics
• TREM2 x APOE bispecifics

Clinical Trial Landscape

Clinical Endpoints

Key endpoints in TREM2-targeted trials include:

• Cognitive measures: ADAS-Cog13, CDR-SB, MMSE
• Biomarkers: CSF sTREM2, [Aβ](/proteins/amyloid-beta) PET, tau PET
• Imaging: MRI brain volume, microglial activation (TSPO PET)
• Safety: Adverse event monitoring

Biomarkers for TREM2-Targeted Therapy

CSF Biomarkers

• sTREM2: Soluble TREM2 fragment in CSF, reflects microglial activation. Changes in sTREM2 can indicate target engagement[@csf2016].
• YKL-40: Chitinase-3-like protein, microglial activation marker
• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Axonal injury marker
• Aβ42/40 ratio: Amyloid status
• Total tau and p-tau: Neurodegeneration markers

Blood Biomarkers

• Plasma sTREM2: Emerging as a peripheral marker of microglial activation
• Plasma [NfL](/proteins/nfl-protein)): Neurodegeneration marker
• Aβ and tau in plasma: Increasingly used for patient selection

Imaging Biomarkers

• PET imaging: Amyloid and tau PET for treatment response
• Microglial PET: TSPO PET to assess microglial activation
• Structural MRI: Brain volume changes

Patient Selection and Stratification

Genetic Considerations

• TREM2 genotype: Patients with TREM2 risk variants may respond differently
• APOE status: APOE ε4 carriers may have altered TREM2 function
• Risk variant carriers: R47H, R62H carriers may benefit from agonistic approaches

Disease Stage

• Preclinical/Prodromal AD: Likely optimal for TREM2 therapies
• Mild Cognitive Impairment (MCI): Active enrollment in trials
• Mild to Moderate AD: Being studied, may have reduced benefit

Biomarker-Based Selection

• Amyloid-positive by PET or CSF
• [Tau](/proteins/tau) burden assessment
• Microglial activation status

Challenges and Considerations

Microglial Heterogeneity

• TREM2 function varies with disease stage
• Need to understand TREM2 role in different microglial states
• Potential for different effects in early vs. late disease
• DAM (Disease-Associated Microglia) phenotype complex

Safety Concerns

• Immune-related adverse effects
• Potential for excessive immune activation
• Long-term effects on microglial function unknown
• Risk of cytokine release

Combination Strategies

TREM2 therapies being explored with:

• Anti-amyloid antibodies ([lecanemab](/therapeutics/lecanemab), donanemab)
• Anti-tau therapies
• Other immunomodulatory approaches
• Potential synergies with BACE inhibitors (caution due to toxicity)

Pharmacokinetic Challenges

• Antibody brain penetration is limited
• Need for engineered antibodies with enhanced brain delivery
• Dose optimization challenging

Future Directions

Next-Generation TREM2 Therapeutics

• Bispecific antibodies targeting TREM2 and other pathways
• Small molecules with improved brain penetration
• Cell-type specific delivery systems
• Engineered TREM2 variants

Patient Selection

• TREM2 genotype-based patient stratification
• Biomarker-driven patient selection
• APOE status consideration
• Microglial activation status assessment

Disease Modifying Potential

• Early intervention likely most effective
• Potential for prevention trials in at-risk individuals
• Long-term treatment effects under investigation

Emerging Research Areas

• TREM2 in Parkinson disease
• TREM2 in ALS
• TREM2 in multiple sclerosis
• TREM2 in frontotemporal dementia

TREM2 and Other Neurodegenerative Diseases

Parkinson Disease

TREM2 variants have been associated with increased PD risk in some studies. Microglial activation is a hallmark of PD, and TREM2-mediated phagocytosis may be relevant to [alpha-synuclein](/proteins/alpha-synuclein) clearance.

ALS

TREM2 expression is elevated in ALS, and genetic variants may modify disease progression. Clinical trials in ALS are being considered.

Multiple Sclerosis

TREM2 plays a role in microglial responses in demyelinating diseases. TREM2 may be protective in MS models.

Background

The study of Trem2 Targeting Therapies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

See Also

• [Treatments Index](/therapeutics)
• [Alzheimer Disease](/diseases/alzheimers-disease)
• [TREM2 Gene](/genes/trem2)
• [TREM2 Protein](/proteins/trem2-protein)
• [Microglia](/cell-types/microglia)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-hypothesis)
• [Microglia in Neurodegeneration](/cell-types/microglia)
• APOE and Neurodegeneration

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [TREM2-Dependent Microglial Senescence Transition](/hypothesis/h-61196ade) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: TREM2
• [Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
• [Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
• [APOE-TREM2 Interaction Modulation](/hypothesis/h-180807e5) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: TREM2
• [Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: CSGA
• [TREM2-Mediated Selective Aggregate Clearance Pathway](/hypothesis/h-3460f820) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: TREM2
• [Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting](/hypothesis/h-3a4f2027) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: HTT, DMPK, repeat-containing transcripts

• [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-01-gap-001) &#x1f504;
• [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-02-gap-001) &#x1f504;
• [Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;